Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Gilead Sciences Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Accounts payable 550 905 705 844 713
Accrued rebates 3,802 3,479 3,244 3,460 3,473
Compensation and employee benefits 1,201 1,018 927 864 599
Income taxes payable 1,208 959 539 598 287
Allowance for sales returns 387 422 499 587 137
Accrual for settlement related to bictegravir litigation 1,250
Other 2,334 2,181 2,930 2,287 2,051
Other current liabilities 5,130 4,580 6,145 4,336 3,074
Current portion of long-term debt and other obligations, net 1,798 2,273 1,516 2,757 2,499
Current liabilities 11,280 11,237 11,610 11,397 9,759
Long-term debt, net, excluding current portion 23,189 22,957 25,179 28,645 22,094
Long-term income taxes payable 2,039 3,916 4,767 5,016 6,115
Deferred tax liability 1,588 2,673 4,356 3,914
Other long-term obligations 1,280 1,179 976 1,214 1,009
Long-term liabilities 28,096 30,725 35,278 38,789 29,218
Total liabilities 39,376 41,962 46,888 50,186 38,977
Preferred stock, par value $0.001 per share; none outstanding
Common stock, par value $0.001 per share 1 1 1 1 1
Additional paid-in capital 6,500 5,550 4,661 3,880 3,051
Accumulated other comprehensive income (loss) 28 2 83 (60) 85
Retained earnings 16,304 15,687 16,324 14,381 19,388
Total Gilead stockholders’ equity 22,833 21,240 21,069 18,202 22,525
Noncontrolling interest (84) (31) (5) 19 125
Total stockholders’ equity 22,749 21,209 21,064 18,221 22,650
Total liabilities and stockholders’ equity 62,125 63,171 67,952 68,407 61,627

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Gilead Sciences Inc. current liabilities decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Gilead Sciences Inc. long-term liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Gilead Sciences Inc. total liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total Gilead stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Gilead Sciences Inc. total Gilead stockholders’ equity increased from 2021 to 2022 and from 2022 to 2023.